Pulmonary Hypertension: Could CBD Be the Answer?

Pulmonary hypertension is a serious medical condition that affects the pulmonary arteries, leading to increased pressure and dysfunction of the heart and lungs. Conventional treatments aim to alleviate symptoms and slow the progression of the disease, but many patients are seeking alternative and natural therapeutic options. In this quest, cannabidiol (CBD), a compound derived from cannabis, is emerging as a promising avenue.

CBD is attracting growing interest due to its unique pharmacological properties. Unlike tetrahydrocannabinol (THC), another component of cannabis, CBD has no psychoactive effects and is generally well tolerated by users. Preclinical studies have shown that CBD may have beneficial effects on the regulation of pulmonary arterial pressure, thereby opening up new possibilities for the treatment of pulmonary hypertension.

In this article, we will explore current research on the use of CBD as a potential treatment for pulmonary hypertension. Although further studies are needed to confirm the efficacy and safety of CBD in treating pulmonary hypertension, its natural properties and promising results make it an avenue of interest for patients and researchers.

Pulmonary hypertension is a complex medical condition characterized by high blood pressure in the blood vessels of the lungs. This condition causes increased resistance in the pulmonary arteries, which puts additional strain on the right side of the heart and can lead to heart failure. Understanding the mechanisms of pulmonary hypertension is essential for evaluating CBD’s potential as a therapeutic alternative.

Pulmonary hypertension is generally defined as a mean pulmonary arterial pressure greater than 25 mmHg at rest, as measured during right heart catheterization. It can be classified into five groups according to the WHO classification, based on its underlying causes. These groups include pulmonary hypertension due to heart disease, chronic lung disease, chronic thromboembolic disease, pulmonary vascular disease, and undetermined causes.

Pulmonary hypertension can be caused by several factors. Heart diseases, such as congenital heart defects, valvular heart disease, and left heart failure, can lead to pulmonary hypertension due to increased pressure in the pulmonary vessels. Chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, can also contribute to pulmonary hypertension due to impaired blood flow in the lungs. In addition, genetic factors, chronic infections, autoimmune disorders, and exposure to environmental toxins may also be associated with pulmonary hypertension.

Conventional treatments for pulmonary hypertension are primarily aimed at reducing pulmonary arterial pressure, relieving symptoms, and slowing the progression of the disease. They include the use of pulmonary vasodilators such as phosphodiesterase-5 inhibitors (PDE-5 inhibitors), endothelin receptor antagonists (ERAs), and prostanoids. These medications work by relaxing the pulmonary blood vessels, improving blood flow, and reducing the workload on the heart. In severe cases, a lung transplant may be considered for patients who do not respond to drug treatments.

Although conventional treatments can relieve symptoms and improve patients’ quality of life, they have certain limitations and side effects. Certain medications can cause adverse effects such as headaches, nausea, hot flashes, and muscle pain. In addition, the long-term use of certain vasodilators may be limited due to tolerance, the need for frequent dose adjustments, and the high cost of some medications.

Cannabidiol (CBD) is a natural chemical compound belonging to the cannabinoid family, found in the cannabis plant. Unlike tetrahydrocannabinol (THC), another well-known cannabinoid, CBD has no psychoactive effects, which means it does not cause euphoria or intoxication. CBD is extracted from various varieties of cannabis, such as industrial hemp, which contain low levels of THC.

CBD can be extracted from cannabis plants using various methods, including solvent extraction, supercritical CO2 extraction, and ethanol extraction. Each method has its advantages and disadvantages in terms of efficiency, purity, and safety. Once extracted, CBD can be used in the form of oil, capsules, topical creams, or even edibles.

CBD interacts with the human body’s endocannabinoid system (ECS), which plays a key role in regulating various physiological processes, such as pain, inflammation, mood, sleep, and appetite. CBD works by binding to the endocannabinoid system’s cannabinoid receptors—primarily the CB1 and CB2 receptors—thereby modulating the responses of the central nervous system and the immune system. In addition, CBD also exhibits anti-inflammatory, antioxidant, anxiolytic, and neuroprotective properties.

CBD has been studied for its therapeutic potential in many medical fields. Currently, CBD is approved for use in the treatment of certain forms of epilepsy, such as Lennox-Gastaut syndrome and Dravet syndrome, where it has demonstrated significant efficacy in reducing seizures. In addition, CBD is used as a complementary treatment to relieve symptoms of anxiety, chronic pain, insomnia, and neurological disorders such as multiple sclerosis and Parkinson’s disease.

Research into the potential uses of CBD is constantly evolving. Preclinical and clinical studies are underway to evaluate the effectiveness of CBD in treating various conditions, including mental health disorders, inflammatory diseases, cardiovascular diseases, and pulmonary hypertension. CBD’s ability to interact with multiple biological pathways opens the door to new therapeutic possibilities.

A three-week course of cannabidiol (CBD) treatment reduced signs of cardiac fibrosis—that is, the accumulation of scar tissue—in a rat model of pulmonary hypertension (PH). These results suggest that CBD may be beneficial for improving cardiac function in patients with PH by inhibiting certain pro-fibrotic signaling pathways. The researchers noted that “further detailed investigations are recommended to confirm our promising results.” The study was published in the journal BBA - Molecular Basis of Disease.
 

PAH is a chronic condition characterized by increased pressure in the pulmonary arteries that carry blood from the heart to the lungs. Over time, PAH is associated with a reorganization of heart tissue, including inflammation, fibrosis (accumulation of scar tissue), and overactivation of fibroblasts—a type of connective tissue cell involved in fibrosis. These changes can ultimately lead to failure of the right ventricle of the heart, which pumps blood to the lungs.

CBD is the main non-psychoactive component of cannabis. An oral formulation of CBD is marketed under the name Epidiolex for the treatment of seizures in certain patients. Preclinical studies have shown that CBD may be beneficial for the lungs in rat models of pulmonary hypertension (PH). Specifically, it has been shown to reduce thickening of the pulmonary artery walls, alleviate inflammation, and stimulate antioxidant activity in the lungs. Furthermore, an oral formulation of CBD was found to reduce pulmonary arterial pressure in healthy volunteers under conditions mimicking HTP, that is, under low-oxygen conditions.
 

However, its specific effects on the heart in the context of PH have not been studied. CBD has been found to improve cardiac function and reduce cardiac fibrosis and inflammation in other animal models. 
 

Consequently, the research team in Poland set out to study the potential of CBD to combat cardiac fibrosis in a rat model of HTP. Rats with HTP and their healthy counterparts received daily injections of CBD or a placebo for three weeks, after which their right ventricles were examined for signs of fibrosis.
 

The results showed that rats with HTP had elevated blood levels of NT-proBNP, a marker of heart failure, compared to healthy rats. CBD treatment significantly reduced NT-proBNP levels in the HTP model, bringing them down to levels similar to those in healthy animals. Furthermore, the HTP rat model was characterized by several changes in cardiac tissue, including an enlargement of cardiomyocytes, or heart muscle cells. Larger cardiomyocytes indicate a thickening of the heart walls. Three weeks of CBD treatment resulted in an approximately 10% reduction in cardiomyocyte width and a 70% reduction in right ventricular fibrosis compared to the placebo group.

In conclusion, preliminary results suggest that cannabidiol (CBD) shows promising potential for improving cardiac function in patients with pulmonary hypertension (PH). The study using a rat model of PH showed that three weeks of CBD treatment reduced signs of cardiac fibrosis, such as the accumulation of scar tissue. This reduction in fibrosis was associated with improved cardiac performance, including a decrease in pulmonary arterial pressure and a reduction in heart wall thickening.
 

These findings pave the way for further research into the potential use of CBD in the treatment of HTP. However, it is important to note that this study is still preliminary and that further detailed investigation is needed to confirm these promising results. Clinical studies in patients with HTP will be necessary to evaluate the efficacy and safety of CBD as an adjunctive treatment.

It is also worth noting that CBD is the main non-psychoactive component of cannabis, and it is already approved for the treatment of seizures in certain patients. Its safety profile has been well studied, making it an attractive candidate for further research in the context of HTP.
 

In summary, although CBD shows promising potential, further research is essential to better understand its mechanism of action, optimal dosage, and interaction with other treatments used for HTP. These advances could open up new therapeutic possibilities and offer hope to patients suffering from this chronic, debilitating disease.